Inhalation Sciences receives new order worth 360,000 SEK from long-term global pharma client
(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required software update work from a long-term client, a leading global pharmaceutical company.
The client has an extensive generics pipeline and robust R&D organisation. It has ISAB’s high-precision aerosol generation system PreciseInhale® installed in-house, as well as its in vitro lung simulation module DissolvIt®. Prior to purchase and installation, the client carried out a series of successful clinical research projects with Inhalation Research Services - ISAB’s contract research team. The current purchase order is for development work and required software upgrades.
ISAB CEO Manoush Masarrat: “We are pleased to continue this long and much-valued relationship. Our technology has proved itself every step of the way for our client. Now our development and software service work will ensure that this excellent performance continues.”
Read more about PreciseInhale® here
PreciseInhale® is ISAB’s aerosol generation system that enables precision dosing across a range of in vitro and in vivo exposure modules. PreciseInhale® has now also been validated for clinical use.
Read more about DissolvIt® here
DissolvIt® is ISAB’s leading in vitro lung dissolution module, delivering high-precision, predictive in vitro in vivo correlated (IVIVC) data. The US FDA has now approved ISAB’s proposal for a research study aiming to validate DissolvIt® as an FDA-recommended technology, and will support and co-finance the study.
